Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology

Excellent pre-analytical stability is an essential precondition for reliable molecular profiling of circulating tumor DNA (ctDNA) in oncological diagnostics. Therefore, in vitro degradation of ctDNA and the additional release of contaminating genomic DNA from lysed blood cells must be prevented. Streck Cell-Free DNA blood collection tubes (cfDNA BCTs) have proposed advantages over standard K2EDTA tubes, but mainly have been tested in healthy individuals. Blood was collected from cancer patients (n = 53) suffering from colorectal (n = 21), pancreatic (n = 11), and non-small-cell lung cancer (n = 21) using cfDNA BCT tubes and K2EDTA tubes that were processed immediately or after 3 days (BCTs) or 6 hours (K2EDTA) at room temperature. The cfDNA isolated from these samples was characterized in terms of yield using LINE-1 qPCR; the level of gDNA contamination; and the mutation status of KRAS, NRAS, and EGFR genes using BEAMing ddPCR. CfDNA yield and gDNA levels were comparable in both tube types and were not affected by prolonged storage of blood samples for at least 3 days in cfDNA BCTs or 6 hours in K2EDTA tubes. In addition, biospecimens collected in K2EDTA tubes and cfDNA BCTs stored for up to 3 days demonstrated highly comparable levels of mutational load across all respective cancer patient cohorts and a wide range of concentrations. Our data support the applicability of clinical oncology specimens collected and stored in cfDNA BCTs for up to 3 days for reliable cfDNA and mutation analyses.

[1]  S. Holdenrieder,et al.  New Perspectives on the Importance of Cell-Free DNA Biology , 2022, Diagnostics.

[2]  S. Holdenrieder,et al.  Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures , 2022, Diagnostics.

[3]  S. Holdenrieder,et al.  Preanalytical variables that affect the outcome of cell-free DNA measurements , 2020, Critical reviews in clinical laboratory sciences.

[4]  Helen M Moore,et al.  Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance , 2020, Clinical Cancer Research.

[5]  F. Mouliere,et al.  Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA. , 2019, Cancer cell.

[6]  M. Black,et al.  Comparison of Roche Cell-Free DNA collection Tubes® to Streck Cell-Free DNA BCT®s for sample stability using healthy volunteers , 2019, Practical laboratory medicine.

[7]  A. Thierry,et al.  Guidelines for the Preanalytical Conditions for Analyzing Circulating Cell-Free DNA. , 2019, Clinical chemistry.

[8]  Tae-Dong Jeong,et al.  Effects of Pre-analytical Variables on Cell-free DNA Extraction for Liquid Biopsy , 2019, Laboratory Medicine Online.

[9]  S. Holdenrieder,et al.  The emerging role of cell-free DNA as a molecular marker for cancer management , 2019, Biomolecular detection and quantification.

[10]  C. Sohn,et al.  Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies , 2019, International journal of molecular sciences.

[11]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[12]  N. Rosenfeld,et al.  Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients , 2018, The Journal of molecular diagnostics : JMD.

[13]  R. Büttner,et al.  Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing. , 2017, The Journal of molecular diagnostics : JMD.

[14]  M. Cowley,et al.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma , 2017, Molecular Diagnosis & Therapy.

[15]  N. Lambrecht,et al.  Liquid biopsy - Performance of the PAXgene® Blood ccfDNA Tubes for the isolation and characterization of cell-free plasma DNA from tumor patients. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[16]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[17]  Stefan Sleijfer,et al.  Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[18]  S. Merajver,et al.  Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. , 2016, Clinical biochemistry.

[19]  F. Diehl,et al.  Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing , 2016, PloS one.

[20]  V. Velculescu,et al.  The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA , 2016, Clinical Cancer Research.

[21]  G. Schiavon,et al.  Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer , 2016, PloS one.

[22]  P. Jiang,et al.  The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics. , 2016, Trends in genetics : TIG.

[23]  A. Kohlmann,et al.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) , 2016, PloS one.

[24]  D. Chia,et al.  Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB). , 2016, The Analyst.

[25]  Crispin J. Miller,et al.  Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample , 2015, Molecular oncology.

[26]  Mario Pazzagli,et al.  Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas External Quality Assessment experience , 2015, Clinical chemistry and laboratory medicine.

[27]  A. Bronkhorst,et al.  Cell-free DNA: Preanalytical variables. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[28]  B. Park,et al.  Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. , 2015, Clinical biochemistry.

[29]  B. Dréno,et al.  Efficient Detection of BRAF Mutation in Plasma of Patients after Long-term Storage of Blood in Cell-Free DNA Blood Collection Tubes. , 2015, Clinical chemistry.

[30]  T. Williams,et al.  A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. , 2013, Clinical biochemistry.

[31]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[32]  David Wong,et al.  Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. , 2013, Clinical biochemistry.

[33]  J. Qin,et al.  A New Blood Collection Device Minimizes Cellular DNA Release During Sample Storage and Shipping When Compared to a Standard Device , 2013, Journal of clinical laboratory analysis.

[34]  S. Holdenrieder,et al.  Methods for isolation of cell-free plasma DNA strongly affect DNA yield. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[35]  A. Barrett,et al.  Implementing Prenatal Diagnosis Based on Cell-Free Fetal DNA: Accurate Identification of Factors Affecting Fetal DNA Yield , 2011, PloS one.

[36]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[37]  S. Norton,et al.  A new methodology to preserve the original proportion and integrity of cell‐free fetal DNA in maternal plasma during sample processing and storage , 2010, Prenatal diagnosis.

[38]  K. Kinzler,et al.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.

[39]  Frank Diehl,et al.  BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions , 2006, Nature Methods.

[40]  H. Scher,et al.  Toward Standardization of Preanalytical Procedures for Cell-Free DNA Profiling. , 2019, Clinical chemistry.

[41]  T. Schlange,et al.  Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. , 2019, Clinical chemistry.

[42]  J. Distler,et al.  Evaluation of Different Blood Collection Tubes and Blood Storage Conditions for the Preservation and Stability of Cell-Free Circulating DNA for the Analysis of the Methylated mSEPT9 Colorectal Cancer Screening Marker. , 2016, Advances in experimental medicine and biology.